- Home
- CLLS vs AGD Comparison
CLLS vs AGD Comparison
Compare CLLS & AGD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLLS
- AGD
- Stock Information
- Founded
- CLLS 1999
- AGD 2006
- Country
- CLLS France
- AGD United Kingdom
- Employees
- CLLS N/A
- AGD N/A
- Industry
- CLLS Biotechnology: Pharmaceutical Preparations
- AGD Trusts Except Educational Religious and Charitable
- Sector
- CLLS Health Care
- AGD Finance
- Exchange
- CLLS Nasdaq
- AGD Nasdaq
- Market Cap
- CLLS 299.0M
- AGD 302.4M
- IPO Year
- CLLS 2007
- AGD N/A
- Fundamental
- Price
- CLLS $3.79
- AGD $13.81
- Analyst Decision
- CLLS Buy
- AGD
- Analyst Count
- CLLS 1
- AGD 0
- Target Price
- CLLS $4.00
- AGD N/A
- AVG Volume (30 Days)
- CLLS 151.7K
- AGD 61.2K
- Earning Date
- CLLS 11-03-2025
- AGD 01-01-0001
- Dividend Yield
- CLLS N/A
- AGD 8.13%
- EPS Growth
- CLLS N/A
- AGD N/A
- EPS
- CLLS N/A
- AGD N/A
- Revenue
- CLLS $63,438,000.00
- AGD N/A
- Revenue This Year
- CLLS N/A
- AGD N/A
- Revenue Next Year
- CLLS $66.76
- AGD N/A
- P/E Ratio
- CLLS N/A
- AGD N/A
- Revenue Growth
- CLLS 223.09
- AGD N/A
- 52 Week Low
- CLLS $1.10
- AGD $8.20
- 52 Week High
- CLLS $3.83
- AGD $9.78
- Technical
- Relative Strength Index (RSI)
- CLLS 65.98
- AGD 83.31
- Support Level
- CLLS $3.36
- AGD $12.82
- Resistance Level
- CLLS $3.60
- AGD $13.31
- Average True Range (ATR)
- CLLS 0.24
- AGD 0.19
- MACD
- CLLS 0.02
- AGD 0.03
- Stochastic Oscillator
- CLLS 96.95
- AGD 87.07
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
About AGD abrdn Global Dynamic Dividend Fund of Beneficial Interest
Aberdeen Global Dynamic Dividend Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to seek high current dividend income, more than 50% of which qualifies for the reduced federal income tax rate, as created by the Jobs and Growth Tax Relief Reconciliation Act of 2003. The fund also focuses on the long-term growth of capital as a secondary investment objective. The fund's portfolio holdings are in information technology, financials, health care, and consumer discretionary sectors among others.